Crossmark

Cost-effectiveness analysis of PD-L1 testing associated with pembrolizumab for first-line treatment of advanced non-small cell lung cancer in China

Published Online: 2025-01-13

Published Print: 2025-06

Authors

Wu, Yao https://orcid.org/0009-0001-5919-4757
Tao, Libo

Liu, Chang

Wang, Fangxu

Sun, Shuang
License Information

Text and Data Mining valid from 2025-01-13

Version of Record valid from 2025-01-13
More Information

Article History

Received: 23 September 2024

Accepted: 4 January 2025

First Online: 13 January 2025

Conflicts of interest

: The authors have no conflicts of interest to declare.

Document is current